Restoration of latent inhibition by olanzapine but not haloperidol in entorhinal cortex-lesioned rats

被引:19
作者
Coutureau, E [1 ]
Gosselin, O [1 ]
Di Scala, G [1 ]
机构
[1] ULP, CNRS, UMR 7521, Lab Neurosci Comportementales & Cognit, Strasbourg, France
关键词
latent inhibition; entorhinal cortex; haloperidol; olanzapine; schizophrenia; D3; receptor;
D O I
10.1007/s002130000434
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Rationale: Latent inhibition (LI) refers to the decrease in conditioned response induced by the repeated non-reinforced pre-exposure to the conditioned stimulus before its pairing with the unconditioned stimulus during the conditioning stage. LI has been considered as a relevant animal model for the study of the biological bases of schizophrenia. LI has recently been demonstrated to depend on the integrity of the entorhinal cortex, as lesioning: of this area disrupted LI. Objectives: The present study aimed to verify whether the classical neuroleptic haloperidol and/or the atypical antipsychotic olanzapine would prevent the effect of entorhinal cortex lesioning. Methods: LI was studied in an off-baseline conditioned emotional response (CER) paradigm in which a tone is paired with a footshock. Entorhinal cortex lesions were produced by the electrolytic method. After a recovery period, both lesioned and control rats received either haloperidol (0.3 mg/kg), olanzapine (0.3 mg/kg) or vehicle before both the pre-exposure and conditioning stages of the experiment. Results: In control rats, pre-exposure to the tone induced LI, which was affected by neither haloperidol nor olanzapine. Lesioning of the entorhinal cortex produced a deficit of LI, which was restored by olanzapine but not by haloperidol. Conclusions: This result suggests a dissociation of the anatomical and pharmacological targets of the two drugs. The possible involvement of dopamine D3 receptors in the effects of olanzapine is discussed.
引用
收藏
页码:226 / 232
页数:7
相关论文
共 53 条
[11]   Entorhinal but not hippocampal or subicular lesions disrupt latent inhibition in rats [J].
Coutureau, E ;
Galani, R ;
Gosselin, O ;
Majchrzak, M ;
Di Scala, G .
NEUROBIOLOGY OF LEARNING AND MEMORY, 1999, 72 (03) :143-157
[12]  
Deutch AY, 1996, SYNAPSE, V23, P182, DOI 10.1002/(SICI)1098-2396(199607)23:3<182::AID-SYN7>3.0.CO
[13]  
2-4
[14]   EFFECTS OF ANTIPSYCHOTIC-DRUGS ON LATENT INHIBITION - SENSITIVITY AND SPECIFICITY OF AN ANIMAL BEHAVIORAL-MODEL OF CLINICAL DRUG-ACTION [J].
DUNN, LA ;
ATWATER, GE ;
KILTS, CD .
PSYCHOPHARMACOLOGY, 1993, 112 (2-3) :315-323
[15]  
Ellenbroek B.A., 1990, Behav Pharmacol, V1, P469
[16]   EFFECTS OF TYPICAL AND ATYPICAL NEUROLEPTICS ON FOS PROTEIN EXPRESSION IN THE RAT FOREBRAIN [J].
FINKJENSEN, A ;
KRISTENSEN, P .
NEUROSCIENCE LETTERS, 1994, 182 (01) :115-118
[17]   DOPAMINE D2 RECEPTOR EXPRESSION IN HIPPOCAMPUS AND PARAHIPPOCAMPAL CORTEX OF RAT, CAT, AND HUMAN IN RELATION TO TYROSINE HYDROXYLASE-IMMUNOREACTIVE FIBERS [J].
GOLDSMITH, SK ;
JOYCE, JN .
HIPPOCAMPUS, 1994, 4 (03) :354-373
[18]  
Gosselin G, 1996, BEHAV PHARMACOL, V7, P820
[19]   THE NEUROPSYCHOLOGY OF SCHIZOPHRENIA [J].
GRAY, JA ;
FELDON, J ;
RAWLINS, JNP ;
SMITH, AD ;
HEMSLEY, DR .
BEHAVIORAL AND BRAIN SCIENCES, 1991, 14 (01) :1-19
[20]   RECEPTOR MECHANISMS MEDIATING CLOZAPINE-INDUCED C-FOS EXPRESSION IN THE FOREBRAIN [J].
GUO, N ;
KLITENICK, MA ;
THAM, CS ;
FIBIGER, HC .
NEUROSCIENCE, 1995, 65 (03) :747-756